Side-by-side · Research reference

AOD-9604vsLL-37

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2HUMAN-REVIEWED10/47 cited

BHuman-MechanisticHUMAN-REVIEWED15/35 cited

AOD-9604

HGH 176-191 · β3-AR Lipolytic

250–300 mcgDaily doseHeffernan 2001

Phase 2Evidence levelHeffernan 2001 Ng 2000

~30 minHalf-life

SQ · Abdomen · Daily fasted

LL-37

Cathelicidin · Human AMP

Broad-spectrumAntimicrobial activity

Membrane disruptionPrimary mechanismLu 2026 He 2026

Innate immunityHost defense rolePinheiro 2026 Zhang 2026

Endogenous · Secreted at inflammation sites

01Mechanism of Action

Parameter

AOD-9604

LL-37

Primary target

β3-adrenergic receptor (proposed)Ng 2000

Bacterial membranes · Phosphatidylserine-exposed cellsHe 2026 Lu 2026

Pathway

β3-AR activation → cAMP → hormone-sensitive lipase activation → triglyceride breakdown to FFA + glycerolNg 2000

hCAP-18 precursor → Proteinase-3 cleavage → LL-37 release → Membrane insertion/disruption

Downstream effect

Lipolysis of adipose tissue triglycerides; FFA release for oxidation; minimal IGF-1 / insulin impactHeffernan 2001

Membrane permeabilization, cytokine induction, autophagy, phagosome-lysosome fusion, chemotaxisAhmad 2026 Zhang 2026

Feedback intact?

No GH-axis or IGF-1 feedback

—

Origin

Synthetic modified C-terminal hexadecapeptide fragment of human GH (176-191) with N-terminal Tyr substitutionNg 2000

Endogenous human cathelicidin (37-AA fragment, residues 134–170 of hCAP-18)

Antibody development

—

02Dosage Protocols

Parameter

AOD-9604

LL-37

Standard dose

250–300 mcg / dayHeffernan 2001

Anecdotal SQ range. Phase 2 trial dose 1 mg/day oral.

—

Frequency

Once daily, fasted

—

Lower / starter dose

150 mcg / day

—

Evidence basis

Phase 2 trials + animal-strongHeffernan 2001 Ng 2000

In vitro, animal models, human observational

Duration

8–12 weeks per cycle

—

Reconstitution

Bacteriostatic water, 1 mL per 2 mg vial → 2 mg/mL

—

Timing

Morning fasted preferred (pre-cardio)

Aligns with circadian lipolysis.

—

Half-life

~30 min plasma

—

Endogenous expression

—

Constitutive in neutrophils, epithelial tissues

Upregulated during infection and inflammation.Pinheiro 2026

Exogenous (experimental)

—

Dose varies by study; antimalarial ~10–50 μM in vitro

No FDA-approved exogenous formulation.

Plasma levels (malaria)

—

Elevated in infected patients and miceHe 2026

Exogenous administration reduced parasitemia in murine models.He 2026

04Side Effects & Safety

Parameter

AOD-9604

LL-37

Injection site reaction

Mild erythema

—

GI symptoms

Rare mild nausea

—

Cardiovascular

Possible mild HR increase via β3-AR (theoretical β1 cross-reactivity)

—

IGF-1 elevation

None — designed to lack GH-axis activityHeffernan 2001

—

Insulin sensitivity

Neutral — no glucose impairmentHeffernan 2001

—

Cancer risk

No GH/IGF-1 axis activity → lower theoretical risk vs HGH

—

Pregnancy / OB

Avoid

—

Cytotoxicity (high dose)

—

Membrane disruption in host cells at supraphysiological concentrations

Pro-inflammatory signaling

—

Can exacerbate inflammation in certain contexts (context-dependent)Pinheiro 2026

Biofilm formation risk

—

LL-37-DNA complexes may stabilize dental plaque biofilmsTanabe 2026

Theoretical cancer risk

—

Immunomodulatory roles in tumor microenvironment under investigation

Absolute Contraindications

AOD-9604

·Pregnancy / breastfeeding
·Severe cardiovascular disease (caution with β-receptor agonists)

LL-37

—

Relative Contraindications

AOD-9604

·Concurrent β-blocker therapy (theoretical antagonism)
·Pheochromocytoma

LL-37

·Active autoimmune disease (theoretical immune dysregulation)

05Administration Protocol

Parameter

AOD-9604

LL-37

1. Reconstitution

Add 1 mL bacteriostatic water to 2 mg vial → 2 mg/mL = 200 mcg per 0.1 mL.

LL-37 is constitutively expressed in neutrophils and epithelial cells, cleaved from hCAP-18 by proteinase-3 at sites of infection or inflammation.

2. Injection site

SQ — abdomen preferred. Rotate sites.

Synthetic LL-37 and derivatives (e.g., SAMP-12aa) tested in vitro and animal models. Administered via topical, intraperitoneal, or intravenous routes in research settings.

3. Timing

Morning, fasted, ideally pre-cardio for amplified fat oxidation.

LL-37 is resistant to pepsin degradation at gastric pH. Synthetic short peptides designed to retain this stability while reducing toxicity.Lu 2026

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.

—

5. Needle

29–31G, 4–8 mm insulin syringe.

—

06Stack Synergy

AOD-9604

+ MOTS-c

Moderate

View MOTS-c →

AOD-9604 mobilises FFAs from adipose via β3-AR; MOTS-c upregulates AMPK / PGC-1α / FAO machinery so that mobilised FFAs are efficiently oxidised. The pathways are sequential — supply (AOD) plus demand (MOTS-c) — and produce more durable lipolytic effects than either alone in anecdotal protocols.

AOD-9604: 250–300 mcg SQ · morning fasted (daily)
MOTS-c: 5 mg SQ · 2–3× per week (pre-workout)
Primary benefit: Fat mobilisation + mitochondrial oxidation, no IGF-1 concern

LL-37

— no documented stacks